These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38757158)

  • 1. Success of Ultra-low Dose Radiation Therapy for Primary Cutaneous B-cell Lymphoma.
    Onyewadume L; McClelland S
    Am J Clin Oncol; 2024 Sep; 47(9):431-433. PubMed ID: 38757158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation.
    Repka MC; Aghdam N; Kataria SK; Campbell L; Suy S; Collins SP; Anderson E; Lischalk JW; Collins BT
    Radiat Oncol; 2017 Oct; 12(1):162. PubMed ID: 29052514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
    Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
    Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of patients with non-Hodgkin's lymphoma treated with Bexxar with or without external-beam radiotherapy.
    Smith K; Byer G; Morris CG; Kirwan JM; Lightsey J; Mendenhall NP; Hoppe BS; Lynch J; Olivier K
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1122-7. PubMed ID: 21570217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy, curative potential, and prognostic factors of radiotherapy in primary cutaneous B-cell lymphoma.
    Eich HT; Eich D; Micke O; Süttzer H; Casper C; Krieg T; Müller RP
    Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):899-906. PubMed ID: 12605967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy.
    Akhtari M; Reddy JP; Pinnix CC; Allen PK; Osborne EM; Gunther JR; Milgrom SA; Smith GL; Wogan CF; Fowler N; Rodriguez MA; Dabaja B
    Leuk Lymphoma; 2016; 57(1):34-8. PubMed ID: 25860237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study.
    Ciabattoni A; Gregucci F; Fastner G; Cavuto S; Spera A; Drago S; Ziegler I; Mirri MA; Consorti R; Sedlmayer F
    Breast Cancer Res; 2021 Apr; 23(1):46. PubMed ID: 33849606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two fractions of high-dose-rate brachytherapy in the management of cervix cancer: clinical experience with and without chemotherapy.
    Sood BM; Gorla G; Gupta S; Garg M; Deore S; Runowicz CD; Fields AL; Goldberg GL; Anderson PS; Vikram B
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):702-6. PubMed ID: 12062615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
    Abrams RA; Grochow LB; Chakravarthy A; Sohn TA; Zahurak ML; Haulk TL; Ord S; Hruban RH; Lillemoe KD; Pitt HA; Cameron JL; Yeo CJ
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1039-46. PubMed ID: 10421536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancer.
    Parzen JS; Ye H; Gustafson G; Yan D; Martinez A; Chen PY; Ghilezan M; Sebastian E; Limbacher A; Krauss DJ
    Radiother Oncol; 2020 Jun; 147():123-129. PubMed ID: 32276193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose-rate (HDR) or pulsed-dose-rate (PDR) perioperative interstitial intensity-modulated brachytherapy (IMBT) for local recurrences of previously irradiated breast or thoracic wall following breast cancer.
    Niehoff P; Dietrich J; Ostertag H; Schmid A; Kohr P; Kimmig B; Kovács G
    Strahlenther Onkol; 2006 Feb; 182(2):102-7. PubMed ID: 16447017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Safety of Radiotherapy in the Treatment of Primary Cutaneous B-Cell Lymphoma: A Multidisciplinary Systematic Review.
    Di Stefani A; Tagliaferri L; Lancellotta V; Fionda B; Fossati B; Balducci M; Federico F; Hohaus S; De Simone C; Gambacorta MA; Peris K
    Front Oncol; 2020; 10():1133. PubMed ID: 32760672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultra-low dose external beam radiotherapy for presumed choroidal lymphoma: a case report.
    Flanagan JPM; Ng M; Kibrom AZ; Filshie RJA; Stawell RJ; O'Day RF
    J Ophthalmic Inflamm Infect; 2022 Mar; 12(1):10. PubMed ID: 35247125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curative external beam radiotherapy for prostate carcinoma: results in 231 patients treated in Lyon.
    Gerard JP; Xie C; Carrie C; Romestaing P; Pommier P; Mornex F; Clippe S; Sentenac I; Ginestet C
    Aust N Z J Surg; 1999 Oct; 69(10):707-11. PubMed ID: 10527346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of High Dose Rate Interstitial Implant on Early and Locally Advanced Oral Cavity Cancers: Update and Long-Term Follow-Up Study.
    Vedasoundaram P; Raghava Ks A; Periasamy K; Selvarajan G; K S; Kandasamy S; R S; Kumar A
    Cureus; 2020 May; 12(5):e7910. PubMed ID: 32494525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy.
    Lam MG; Abdelmaksoud MH; Chang DT; Eclov NC; Chung MP; Koong AC; Louie JD; Sze DY
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):323-9. PubMed ID: 23849697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas.
    Petersen IA; Haddock MG; Donohue JH; Nagorney DM; Grill JP; Sargent DJ; Gunderson LL
    Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):469-75. PubMed ID: 11872294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.